“Extended Dosing” with Natalizumab – A Sensible Strategy for Reducing the Risk of PML?
Tysabri® (Natalizumab) is undoubtedly a very effective and well-tolerated drug for the treatment of active Multiple Sclerosis. Many patients have benefited from the treatment in the past and were satisfied with the effects and individual
Continue reading




